List of Excipients in Branded Drug LABETALOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	SODIUM HYDROXIDE

Generic Drugs Containing LABETALOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	labetalol hydrochloride	0143-9320	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc	labetalol hydrochloride	0143-9320	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	labetalol hydrochloride	0143-9320	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	labetalol hydrochloride	0143-9320	PROPYLPARABEN

What are the Most Frequently-Used Excipients in LABETALOL HYDROCHLORIDE?

# Of NDCs	Excipient
8	ALUMINUM OXIDE
2	ANHYDROUS CITRIC ACID
21	ANHYDROUS DEXTROSE
40	ANHYDROUS LACTOSE

Labetalol Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Labetalol hydrochloride is a mature generic antihypertensive with established oral and injectable dosage forms. Commercial opportunity is concentrated in excipient-led differentiation: improved tablet manufacturability, low-cost high-volume supply, preservative and osmolality control for injection, pediatric or liquid formulations, and hospital-focused packaging. Originator-style patent exclusivity is not the primary barrier. FDA approval, bioequivalence, product quality, sterile manufacturing, and reliable supply are the principal competitive requirements.

What is labetalol hydrochloride used for?

Labetalol hydrochloride is a combined alpha-1 adrenergic blocker and nonselective beta-adrenergic blocker. Oral products are indicated for hypertension. The injection is used for severe hypertension requiring rapid blood-pressure control, including hospital and perioperative settings (DailyMed, 2024a; DailyMed, 2024b).

Attribute	Oral product	Injectable product
Active ingredient	Labetalol hydrochloride	Labetalol hydrochloride
Common strengths	100 mg, 200 mg, 300 mg tablets	5 mg/mL solution
Primary setting	Chronic outpatient hypertension	Hospital and emergency hypertension management
FDA pathway	NDA and multiple ANDAs	NDA and multiple ANDAs
Key quality risks	Dissolution, content uniformity, tablet robustness	Sterility, particulate matter, pH, osmolality, container closure
Main commercial buyers	Retail pharmacies, wholesalers, health systems	Hospitals, group purchasing organizations, specialty distributors

Labetalol is also used clinically during pregnancy-related hypertension, although the approved labeling and institutional protocols must be reviewed separately from off-label use. Injectable demand is linked to emergency departments, intensive-care units, obstetric hospitals, and perioperative care.

What excipients are used in labetalol hydrochloride tablets?

Commercial labetalol tablets use conventional solid-dose excipients. Product-specific compositions differ by manufacturer and strength. FDA labeling identifies excipients such as microcrystalline cellulose, lactose, starch, magnesium stearate, colloidal silicon dioxide, and film-coating materials in various products (DailyMed, 2024a; DailyMed, 2024c).

Excipient class	Typical function	Commercial rationale
Microcrystalline cellulose	Filler, dry binder, disintegrant support	Improves compression and tablet strength
Lactose monohydrate	Diluent	Low-cost volume and favorable processing
Pregelatinized starch or maize starch	Binder and disintegrant	Supports granulation and breakup
Crospovidone or sodium starch glycolate	Superdisintegrant	Controls tablet disintegration
Colloidal silicon dioxide	Glidant	Improves powder flow and content uniformity
Magnesium stearate	Lubricant	Reduces ejection force
Hypromellose, titanium dioxide, iron oxides	Film coating	Identification, protection, swallowability, and branding

The highest-value excipient decision is usually the manufacturing process rather than any single ingredient. A direct-compression platform can reduce processing steps and cost, but it requires consistent powder flow, segregation control, and robust content uniformity. Wet granulation can improve blend uniformity and tablet strength when the formulation has poor flow or compressibility.

How should excipients be selected for labetalol tablet development?

A practical development sequence is:

1. Establish the target dissolution profile against the reference product.
2. Screen filler-binder systems for flow, compressibility, and tablet tensile strength.
3. Optimize disintegrant level without creating excessive friability or rapid initial release.
4. Control magnesium stearate concentration and mixing time because over-lubrication can slow dissolution.
5. Evaluate lactose compatibility, especially where moisture exposure or aldehyde-related interactions are a concern.
6. Confirm stability in the proposed commercial container closure system.
7. Assess scale-up behavior using the intended commercial tablet press and blending equipment.

Labetalol hydrochloride has high-dose strengths, so excipient efficiency matters. A formulation that requires excessive excipient load can increase tablet size, packaging cost, and patient burden. Strength proportionality across 100 mg, 200 mg, and 300 mg tablets can simplify manufacturing, but each strength must meet its own dissolution and content-uniformity requirements.

What excipient strategies create commercial differentiation?

The strongest opportunities do not depend on new chemical matter. They depend on reducing manufacturing cost or solving a recognized product limitation.

Lactose-free or low-lactose tablets

A lactose-free formulation can target patients with lactose intolerance, institutional formularies with excipient restrictions, and manufacturers seeking a differentiated label. The commercial value is limited because most patients do not require lactose-free labetalol, but the strategy can support a secondary product line with modest formulation complexity.

Low-weight direct-compression tablets

A low-excipient-load formulation can reduce tablet size and improve swallowing. The technical challenge is maintaining blend uniformity across a relatively high drug load. Roller compaction or engineered filler systems may be useful where direct compression produces unacceptable variability.

Improved film coating

A robust film coat can reduce tablet dusting, improve appearance, and support product identification in hospital dispensing systems. Color selection also helps separate 100 mg, 200 mg, and 300 mg strengths, reducing medication-selection errors.

Modified-release oral products

A once-daily or extended-release labetalol product could create a differentiated product if it delivers clinically acceptable exposure and tolerability. Such a product would require a new formulation program, pharmacokinetic bridging, and likely a 505(b)(2) or full NDA strategy rather than a conventional ANDA. The opportunity is technically meaningful but commercially uncertain because inexpensive immediate-release generics set a low price ceiling.

Oral liquid or multiparticulate products

An oral solution, suspension, or sprinkle-compatible multiparticulate product could address pediatric, geriatric, and dysphagia populations. The main development issues are taste masking, chemical stability, dose uniformity, preservative selection, microbial control, and compatibility with dosing devices. A liquid product may have stronger differentiation than another standard tablet, but its market is narrower.

What excipients are used in labetalol hydrochloride injection?

Labetalol hydrochloride injection is commonly supplied as a sterile aqueous solution at 5 mg/mL. Labeling identifies water for injection and sodium chloride in representative products. Hydrochloric acid or sodium hydroxide may be used for pH adjustment depending on the manufacturer and presentation (DailyMed, 2024b; DailyMed, 2024d).

Key injectable quality attributes include:

• Assay and degradation products
• pH and buffer capacity
• Osmolality
• Sterility and bacterial endotoxins
• Visible and subvisible particulates
• Container-closure integrity
• Extractables and leachables
• Light and temperature stability

The injection has a narrower excipient design space than the tablet. Each added excipient increases regulatory and compatibility burden. Sodium chloride can support isotonicity, but the final osmolality must be assessed in the commercial container. A buffer may improve pH control, but it can also affect stability, precipitation behavior, compatibility with infusion fluids, and tolerability.

Which injectable excipient opportunities are commercially attractive?

The most practical opportunities are:

Opportunity	Technical objective	Commercial value
Ready-to-use premixed presentation	Remove bedside dilution	Reduces preparation burden and medication errors
Plastic syringe or infusion container	Improve administration convenience	Supports emergency and obstetric settings
Preservative-free single-dose vial	Minimize preservative exposure	Fits hospital preference for single-dose products
Improved container closure	Reduce oxygen, light, or leachable exposure	Supports longer shelf life and fewer recalls
Higher-concentration presentation	Reduce administration volume	Requires compatibility and dosing validation
Unit-dose packaging	Simplify inventory and administration	Supports automated dispensing and hospital contracts

The strongest near-term opportunity is often packaging and presentation, not a novel excipient. A ready-to-use, unit-dose injectable product can compete on labor reduction and medication safety even when the active ingredient is fully commoditized.

What FDA regulatory status applies to labetalol hydrochloride products?

Labetalol hydrochloride tablets and injection are established FDA products with multiple generic approvals. Generic applicants generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug (FDA, 2024a).

For oral products, the formulation must meet the relevant strength, dosage form, route, labeling, quality, and bioequivalence requirements. Formulation changes involving excipients may alter dissolution or absorption and can trigger additional comparative studies.

For injection, the applicant must establish pharmaceutical equivalence, sterility, stability, container-closure suitability, and compatibility with the proposed presentation. A sterile manufacturing site, validated aseptic process, and compliant quality system are major entry requirements.

What is the Orange Book status of labetalol hydrochloride?

Labetalol hydrochloride is a mature generic market listed through FDA-approved oral and injectable products. Orange Book analysis should focus on the reference-listed drug, approved ANDAs, therapeutic equivalence codes, and any currently listed patents or exclusivity entries (FDA, 2024b).

The commercial position is different from a recently launched branded drug:

Issue	Labetalol hydrochloride market implication
Active ingredient exclusivity	Not the primary barrier
Formulation patents	Potentially relevant only for differentiated products
Method-of-use patents	Limited commercial significance for routine generic entry
Paragraph IV risk	Generally lower than for newly patented products
ANDA competition	The central pricing and market-share pressure
Manufacturing capability	Particularly important for sterile injection
Supply reliability	Important in hospital tenders and shortage-sensitive markets

Orange Book status can change with new listings, delistings, product discontinuations, or FDA administrative updates. Any launch decision should use the current FDA Orange Book and patent-certification record.

When does labetalol hydrochloride lose exclusivity?

The active ingredient has long passed the period associated with ordinary small-molecule market exclusivity. The relevant commercial question is not when labetalol loses basic exclusivity, but whether a specific formulation, delivery system, or method has separate patent or regulatory protection.

For a conventional immediate-release tablet, generic entry is already established. A new applicant normally competes through ANDA approval, pricing, supply, dosage-form differentiation, or a new presentation. An extended-release product, oral liquid, ready-to-use injection, or device-linked presentation could have a separate exclusivity profile if supported by new patents or clinical data.

Which companies are challenging labetalol hydrochloride patents?

The market is primarily a generic competition field rather than an active branded patent dispute. Generic manufacturers may submit Paragraph III or Paragraph IV certifications when patents are listed for a reference product, but the practical risk depends on the current Orange Book record and the specific reference product.

Potential competitive groups include:

• Large generic manufacturers with established tablet capacity
• Contract manufacturers supplying private-label products
• Injectable specialists with sterile fill-finish capability
• Hospital-focused suppliers competing for formulary and group purchasing contracts
• Branded or specialty firms developing differentiated delivery systems

Patent litigation is more likely for a new formulation than for standard labetalol tablets. A Paragraph IV challenge could arise if a new reference product receives listed formulation or method-of-use patents. For legacy immediate-release labetalol, approval timing and manufacturing readiness usually matter more than litigation timing.

What patent estate protects labetalol hydrochloride formulations?

A conventional labetalol hydrochloride tablet has limited practical patent differentiation because the active ingredient and standard dosage forms are mature. Patentable areas may include:

• Extended-release matrix systems
• Taste-masked liquid formulations
• Stable concentrated injectable solutions
• Ready-to-use premixed infusion systems
• Specific excipient ratios
• Particle-size or polymorph control
• Manufacturing processes that improve dissolution or stability
• Container systems that extend shelf life
• Combination products or delivery devices

A formulation patent must provide more than a routine substitution of one conventional excipient for another. Stronger claims usually connect the composition to a measurable performance advantage, such as improved stability, controlled release, reduced degradation, or a specific pharmacokinetic profile.

How strong is the commercial patent estate for labetalol hydrochloride?

The patent estate for standard labetalol hydrochloride products is commercially weak relative to newer branded medicines because generic tablets and injection are widely established. The strongest defensible position would likely come from a differentiated product with:

1. A clinically relevant delivery advantage.
2. Reproducible manufacturing performance.
3. Narrow but enforceable composition or process claims.
4. FDA-approved labeling that supports the commercial use.
5. Evidence that the product cannot be easily designed around.

Excipient-only patents can be vulnerable when competitors can substitute functionally equivalent fillers, binders, lubricants, or coating systems. Manufacturing-process patents may be more valuable when they produce a difficult-to-replicate impurity profile or stability result, although enforcement can be difficult if the process is not visible in the marketed product.

What licensing deals and partnerships could support entry?

Labetalol commercialization can use several partnership models:

Model	Best use
API supply agreement	Lowers development and regulatory burden for small manufacturers
Contract development and manufacturing	Enables tablet or sterile-injection entry without owned facilities
Hospital distribution partnership	Builds injectable volume and formulary access
Private-label licensing	Expands retail and institutional reach
Regional commercialization license	Supports entry in markets where local registration and tenders dominate
Device or packaging partnership	Enables ready-to-use injection or unit-dose delivery

For tablets, the main diligence points are API consistency, impurity control, analytical-method transfer, and annual capacity. For injection, the decisive issues are aseptic capacity, container-closure validation, visual inspection, and supply continuity.

What generic launch risks exist for labetalol hydrochloride?

Generic launch risk is moderate for tablets and higher for injection.

Oral tablet risks

• Price erosion from multiple ANDA holders
• Low switching costs for pharmacies and wholesalers
• Limited differentiation among immediate-release products
• Dissolution failure after scale-up
• Blend segregation and content-uniformity problems
• Excessive tablet size in high-strength formulations
• Retail channel dependence

Injectable risks

• Sterile manufacturing delays
• Batch rejection from particulate or sterility failures
• Container-closure defects
• Hospital contract concentration
• Shortage-driven demand volatility
• Limited qualified fill-finish suppliers
• Additional operational demands for ready-to-use presentations

A low-cost tablet strategy requires manufacturing scale and reliable distribution. An injectable strategy can produce higher contract value but requires more capital, regulatory control, and quality infrastructure.

How does labetalol compare with competing antihypertensive products?

Labetalol competes with widely available beta blockers, alpha-beta blockers, calcium-channel blockers, ACE inhibitors, angiotensin-receptor blockers, and intravenous agents used in acute hypertension.

Product category	Labetalol advantage	Competitive limitation
Oral labetalol	Combined alpha and beta blockade; established use in pregnancy-related hypertension	Multiple daily dosing for immediate-release products
Oral metoprolol	Broad generic availability and strong prescriber familiarity	Less alpha-1 blockade
Oral carvedilol	Alpha-beta activity and heart-failure positioning	Different dosing and tolerability profile
IV nicardipine	Strong hospital use in titratable acute hypertension	Different mechanism and infusion requirements
IV hydralazine	Familiar obstetric use	Less predictable response in some settings
ACE inhibitors and ARBs	Once-daily dosing and broad chronic hypertension use	Not interchangeable in pregnancy

Labetalol’s defensible commercial niche is based on clinical familiarity, hospital protocols, and specific use settings rather than proprietary chemistry.

What is the revenue exposure and market opportunity?

Revenue exposure is concentrated in volume rather than high unit price. Immediate-release tablets are likely to experience continued price pressure as generic supply expands. Injectable products can command better economics when they offer reliable availability, convenient packaging, or reduced preparation time.

The most attractive segments are:

• Hospital injectable supply
• Obstetric and emergency-care products
• Ready-to-use presentations
• Low-cost private-label tablets
• Lactose-free or excipient-restricted tablets
• Pediatric or dysphagia-oriented oral liquids
• Regional markets with fewer qualified suppliers

A portfolio approach can reduce dependence on one product. Standard tablets provide baseline volume. Injectable presentations support institutional contracts. A differentiated liquid or ready-to-use product creates a higher-margin option, but requires more development and regulatory investment.

Key Takeaways

• Labetalol hydrochloride is a mature generic active ingredient with limited value in conventional composition patents.
• Tablet opportunity is primarily manufacturing-driven: direct compression, blend uniformity, low tablet weight, dissolution control, and excipient differentiation.
• Injection opportunity is concentrated in sterile quality, ready-to-use packaging, preservative-free design, and hospital supply reliability.
• Conventional immediate-release tablets face substantial price competition and low switching costs.
• A new extended-release, liquid, multiparticulate, or ready-to-use injectable product could support a differentiated regulatory and patent strategy.
• Paragraph IV and patent-litigation risk is generally lower for legacy generic products than for new labetalol formulations.
• The highest barriers are sterile manufacturing, FDA quality compliance, reliable API supply, and hospital distribution access.
• Commercial diligence should prioritize current Orange Book listings, FDA approval records, product-specific labeling, ANDA competition, and supplier capacity.

Frequently Asked Questions

Can labetalol hydrochloride tablets be reformulated without new clinical trials?

Many conventional excipient changes may be handled within an ANDA development program if the formulation remains pharmaceutically equivalent and meets FDA requirements. Changes that materially affect dissolution, bioavailability, dosage form, or release profile can require additional comparative studies.

Is a lactose-free labetalol tablet commercially viable?

It can support a differentiated product line, but the target market is narrower than the general hypertension market. The commercial case depends on manufacturing cost, labeling differentiation, and access to pharmacy or institutional channels.

Is labetalol hydrochloride injection suitable for a premixed bag?

A premixed presentation may be technically feasible, but it requires validation of concentration, stability, container compatibility, sterility, particulate control, infusion compatibility, and labeling. The commercial benefit is reduced bedside preparation.

Can an extended-release labetalol product obtain new patent protection?

Potentially. Patentability would depend on the release system, composition, manufacturing process, and demonstrated technical effect. Routine use of standard matrix excipients without an unexpected performance advantage would provide a weaker patent position.

Which labetalol product has the greatest manufacturing barrier?

The sterile injectable product has the greatest barrier because it requires validated aseptic processing, sterile fill-finish capacity, container-closure integrity, particulate control, and hospital-grade supply reliability.

References

1. DailyMed. (2024a). Labetalol hydrochloride tablet, film coated: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (2024b). Labetalol hydrochloride injection: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. DailyMed. (2024c). Labetalol hydrochloride tablets: Inactive ingredients and product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. DailyMed. (2024d). Labetalol hydrochloride injection: Description, inactive ingredients, and storage information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2024a). Generic drug facts and abbreviated new drug application requirements. https://www.fda.gov/drugs

6. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm